



Final Appraisal Recommendation

Advice No: 2215 – July 2015

**Magnesium aspartate dihydrate (Magnaspartate®)
243 mg powder for oral solution**

Limited submission by Kora Healthcare

Recommendation of AWMSG

Magnesium aspartate dihydrate (Magnaspartate®) is recommended as an option for use within NHS Wales for the treatment and prevention of magnesium deficiency, as diagnosed by a doctor, in adults, children and adolescents aged from two years.

Additional note(s):

- Magnaspartate® is the first licensed oral magnesium product available in Wales for the treatment and prevention of magnesium deficiency.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2596), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	Kora Healthcare
Date of first issue	July 2015
Last reviewed	March 2019



Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 2215:
Magnesium aspartate dihydrate (Magnaspartate®) 243 mg powder for oral solution. July 2015.

